It is important that patients with MDS be treated by a specialist with experience treating this condition, given its rarity and complexity.
Treatment for MDS depends upon whether a patient has symptoms or not, and whether the disease is progressing. For those with a lower risk of progress, our goal is reduce symptoms, reduce the number of infections, and increase the patient’s quality of life.
For those with a higher risk of progression, our immediate goal is to increase life expectancy and find novels ways to halt the disease, or to treat it, if and when it develops into AML.
Using the most sophisticated techniques, physicians are now able to track molecular and genetic changes in the bone marrow over time.
The Columbia MDS Program is led by Dr. Azra Raza, the world’s foremost expert on this disease, who has studied this condition for over 30 years. Columbia offers the most comprehensive, multidisciplinary approach to MDS and the highest level of patient care. It has also been designated a national Center of Excellence by the Myelodysplastic Syndromes Foundation and offers the following approaches to this condition: